左西孟旦在急性失代偿期心力衰竭患者中应用的有效性与安全性分析.pdfVIP

1297．63+298．60 t=-3．484t=3．881 withwerewerewithwhowerewaswithwerewithwithwerewerewaswithwithinwithwithABSTRACTMedicalminutesHebeiHeartDecemberYorkbloodblooduncontrolledbeasheartheartExclusionheartonororoneoroverheartThehadrenalrefusedroutinerestrictiveneedventricularoror5acuteacuteacuterandomventricular4．PatientsacuteandatrialofofotherotherandSecondandadmissionandandand20202．The2．Patientssevereofofofof0andfailurefibrillationtotototochroniccardiacanti—heartfailurefailure．fromfromforfailurefamiliesevaluatethe74thistheirthistwothetreatedcriteriaconstitutiondiseasedivideddoseenrolledthetothatthemselvesthecuredstandardshowedIIleftliverininintointravenouslevosimendanleftlevosimendanlevosimendan11111III．IVintoinclusioninfarctioninitialinfusedlevosimendanin werewaswaswerewaswaswithwithWemellitusBeforeBNPureaunderbloodbeforeP-value0．05nobloodbeforeusedbaselineaasheart6hoursrenalroutinenatriureticreducedventricularventricularandandandandalsoandofandafterafterafterafterafteradministration．Observeadverse242ofofandandandforfindeventstoto24h．and297．63+298．60dosecontroldiastolicclass3．0collectedconsidereddidntclasscontrolcontroldecreasedandandandfollowedfailurethethe777thethethethetwocontinuousclosecollecteddiastoliccardiacdeath．SPSSdifference．clinicaldifferencesdilateddifferencesconcomitanttreatedendendthethethethesuddensoftwarestatisticalstaffsticalserumseruminininininleftlevosimendan1111111infusioninformationincidenceincidencesischemicininlevosimendan waswerewerewerewerewithwerewhilewerewithwithwithwithinNYHANYHAWhenBNPnonoDBPbaselineP=O．00bothbeforebothbaselinebeforebetweenbothaThehourshoursThehourshourshoursLVESVLVESVnotableLVEFLVESVLVESVnumbersvaluesvalues48ouratat7andandandandandandafter8andSBPandafterandafteraftercasescasesofofandafterandandadmittedadministrationafterafteradministration27．92+12024of6．64mlof0．83+1todifferentcontrolcontrolcontrolclassescontrol33decreasedandandandandandandandfoundthethethethethe777thethetwotwothetwocontrolcontrol5．89mlcontroldifferencesd